Palladone-Sr (Hydromorphone Hydrochloride)

Hydromorphone Hydrochloride, the active ingredient in Palladone‑Sr, is an opioid analgesic presented as a solid dosage form for oral use. It is indicated for the management of moderate to severe pain in adult patients when alternative treatments are inadequate.

GNH USA supplies Palladone‑Sr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Hydromorphone Hydrochloride is an opioid that acts on the central nervous system to relieve pain across several clinical contexts.

- Cancer‑related pain: provides strong analgesia when other opioids are insufficient. - Post‑operative pain: controls moderate to severe pain after major surgery. - Chronic non‑cancer pain: used in carefully selected patients requiring long‑term opioid therapy. - Acute severe pain episodes: offers rapid relief for breakthrough pain attacks. - Palliative care: improves comfort for patients with life‑limiting illnesses.

Adverse reactions to hydromorphone may range from mild to life‑threatening and should be monitored throughout therapy.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset common during opioid initiation. - Constipation: reduced gastrointestinal motility leading to hard stools. - Drowsiness or sedation: central nervous system depression causing sleepiness. - Dizziness: light‑headed sensation, especially when standing quickly. - Dry mouth: reduced salivary flow causing oral discomfort. - Pruritus: mild itching, often localized.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that can be fatal. - Severe hypotension: marked drop in blood pressure. - Acute adrenal insufficiency: rare hormonal imbalance. - Allergic reactions: rash, urticaria, or anaphylaxis. - Dependence and withdrawal: risk of physical dependence with prolonged use. - Neurotoxicity: rare central nervous system toxicity presenting as confusion or seizures.

When prescribing hydromorphone, clinicians should evaluate patient history, comorbidities, and concomitant medications to minimize risk.

- Assess pain severity and prior opioid response: ensure opioid therapy is appropriate. - Evaluate respiratory function: avoid use in patients with compromised breathing. - Review renal and hepatic function: dose adjustments may be needed. - Monitor for signs of abuse or dependence: implement risk mitigation strategies. - Counsel on constipation management: use laxatives or stool softeners prophylactically. - Store at ambient temperature: keep below 25°C, retain original packaging, and protect from moisture.

Hydromorphone may interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Benzodiazepines: combined CNS depression can cause profound sedation or respiratory failure. - CNS depressants (e.g., barbiturates, alcohol): additive respiratory depression risk. - MAO inhibitors: may precipitate severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): increase hydromorphone plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce analgesic effect. - Anticholinergics: may worsen constipation. - Diuretics: can enhance hypotensive effects. - Serotonergic agents: potential for serotonin syndrome when combined with opioids.